Akcea Therapeutics
146 articles about Akcea Therapeutics
-
Akcea and Ionis Announce Late-Breaking Presentation of Data From AKCEA-APO(a)-LRx at the American Heart Association Scientific Sessions
11/8/2018
Akcea Therapeutics, Inc. (NASDAQ: AKCA), an affiliate of Ionis Pharmaceuticals, Inc., and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), today announced that clinical data on AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a), will be presented at the American Heart Association Scientific Sessions in Chicago November 10-12, 2018.
-
Biopharma companies set to release financial reports next week have reported positive news in recent months.
-
Akcea Recognizes First Global Familial Chylomicronemia Syndrome (FCS) Awareness Day
11/2/2018
Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc., today recognizes the inaugural Familial Chylomicronemia Syndrome (FCS) Awareness Day on November 2, 2018.
-
The U.S. Food and Drug Administration gave Akcea Therapeutics and its parent company Ionis Pharmaceuticals the green light for Tegsedi, its treatment for polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.
-
It looks to be a pretty busy week for the U.S. Food and Drug Administration (FDA), with a number of target action dates for various drugs. Some were delayed, and some were already approved, but there are still a number on the schedule. Here’s a look.
-
Akcea and Ionis Report Positive Data from Phase 2 Study of AKCEA-APO(a)-LRx
9/26/2018
Akcea Therapeutics, Inc. and Ionis Pharmaceuticals, Inc. announced positive topline results from a Phase 2 clinical study of AKCEA-APO(a)-LRx in patients with established cardiovascular disease (CVD) and elevated levels of lipoprotein(a), or Lp(a).
-
Akcea Therapeutics, based in Cambridge, Massachusetts, and Ionis Pharmaceuticals, headquartered in Carlsbad, California, released positive topline data from a Phase II trial of AKCEA-APO(a)-LRx in cardiovascular disease and lipoprotein(a).
-
A patient advocacy organization is putting its weight behind an effort to urge the U.S. Food and Drug Administration to reconsider its recent decision to reject a treatment for the rare lipid disorder familial chylomicronemia syndrome (FCS). That rejection lead to a round of layoffs at Akcea.
-
The biotech industry is fast-moving and dynamic, and staying on top of all the news can be hard for our busy readers. Here’s a look back at some of the top stories you may have missed this month.
-
A betting man may have placed a pretty strong wager on the U.S. Food and Drug Administration’s approval of Akcea Therapeutics’ Waylivra (volanesorsen), a treatment for the rare lipid disorder familial chylomicronemia syndrome (FCS).
-
This week has several action dates by the U.S. Food and Drug Administration (FDA) for a range of indications, including acne, intra-abdominal infections, and rare liver diseases. Here’s a look.
-
Beyond developing novel therapies for serious and rare diseases including FCS, Akcea is also dedicated to supporting the broader needs of the communities they serve.
-
The U.S. Food and Drug Administration (FDA) approved Alnylam Pharmaceuticals’ Onpattro (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults. It is the first and only RNA interference (RNAi) therapeutic to ever be approved.
-
Akcea Therapeutics and PTC Therapeutics Collaborate to Commercialize Two Rare Disease Drugs in Latin America
8/2/2018
PTC in-licenses regional rights to TEGSEDI™ and WAYLIVRA™ from Akcea
-
Akcea Announces Publication of Study Results Showing Multiple Benefits of Patient-to-Patient Connectivity in FCS
7/31/2018
Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals Inc., focused on developing and commercializing drugs to treat people with serious and rare diseases, today announced the publication of results from the first-ever study demonstrating the benefits of patient-to-patient connectivity in the management of familial chylomicronemia syndrome (FCS).
-
European Committee recommends Alnylam’s drug be approved for adults with stage 1 or stage 2 polyneuropathy.
-
New England Journal of Medicine Publishes Results from Pivotal Study of TEGSEDI™ (inotersen) for the Treatment of Hereditary ATTR Amyloidosis
7/5/2018
TEGSEDI treatment demonstrated substantial improvement in measures of neuropathy progression and quality of life
-
Webcast Alert: Ionis Pharmaceuticals Provides Corporate Update at 2018 Annual Meeting of Stockholders
5/23/2018
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a general corporate update in conjunction with its 2018 Annual Meeting of Stockholders and Open House on Wednesday, May 23 at 2:10 p.m. Pacific Time (5:10 p.m. Eastern Time) in Carlsbad, CA.
-
Akcea Therapeutics is preparing for the possible launch of its therapeutic for the treatment of the rare lipid disorder familial chylomicronemia syndrome (FCS) following the thumbs up from a U.S. Food and Drug Administration advisory committee.
-
To ask the question, “What are the top biotech stocks?” is to get trapped in a maze of definitions: small cap versus large cap, upcoming catalysts, trending, or a byzantine series of technical evaluations. Rather than to attempt an overall view, here are a variety of biotech stocks that are worth...